ArticleCase reports in hematology2022
Spontaneous Complete Remission of Acute Myeloid Leukemia in the Absence of Disease-Modifying Therapy following Severe Pulmonary Involvement by Coronavirus Infectious Disease-19.
Article in Case reports in hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 10 citations in OpenAlex.
- Emerging and Re-Emerging Viral Pathogens in Oncolytic Virotherapy: A Comprehensive Review.Reviews in medical virology · 2026Review
- SARS-CoV-2 spike protein exerts an anti-cancer effect in A549 cells in association with MEG3 and BCYRN1 regulation.Scientific reports · 2026Article
- Immune-Genomic Evolution in AML Spontaneous Remission: A 66-Patient Pooled Analysis and Longitudinal Clonal Tracking.Cancers · 2026Article
- Spontaneous Remission of Acute Myeloid Leukemia With MutatedCase reports in hematology · 2026Article
- COVID-19 infection and cancer regression: a review of current evidence, potential mechanisms, and clinical perspectives on a Paradoxical phenomenon.Infectious agents and cancer · 2025Review
- Primary Gastric Extranodal NK/T Cell Lymphoma with T-Cell Phenotype: A Very Rare EBV-Related Locally Involved Aggressive T-Cell Lymphoma Case and the Therapeutic Effects of COVID-19 InfectionTurkish journal of haematology : official journal of Turkish Society of Haematology · 2025Article
- SARS-CoV-2 N protein exerts antitumor effects in NSCLC by inducing DNA damage and augmenting chemotherapeutic sensitivity.Medical oncology (Northwood, London, England) · 2025Article
- SARS-CoV-2 nucleocapsid protein interaction with YBX1 displays oncolytic properties through PKM mRNA destabilization.Molecular cancer · 2024Article
- Tumor reduction after SARS‑CoV‑2 infection in a patient with lung cancer: A case report.Oncology letters · 2024Article
- Tumor lysis syndrome followed by tumor regression after COVID-19 in a patient with chronic lymphocytic leukemia.International cancer conference journal · 2024Article
- New Insights into the Link between SARS-CoV-2 Infection and Renal Cancer.Life (Basel, Switzerland) · 2023Review
- Spontaneous cancer remission after COVID-19: insights from the pandemic and their relevance for cancer treatment.Journal of translational medicine · 2023Review
- SARS-CoV-2 as an Oncolytic Virus Following Reactivation of the Immune System: A Review.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus infectious disease-19 (COVID-19) usually alters the innate and adaptive immune setting by excessive production of proinflammatory cytokines, leading to a deviation in the natural course of simultaneous malignant disease. In the absence of disease-modifying therapy, complete remission of acute myeloid leukemia (AML) is an extraordinary event caused mainly by an immune-related mechanism secondary to a severe infectious process. We present a 57-year-old woman with a new diagnosis of AML associated with a 11q23/KMT2A abnormality who had achieved temporary spontaneous remission in the absence of disease-modifying therapy following the severe pulmonary infection with coronavirus lasting for six months. We review the literature and explain the potential impact of stimulated immune responses by COVID-19 on induction of remission in a patient with AML that could provide an excellent opportunity for new immune-based therapies to evolve for the hematologic malignancies. Despite the high ability of the immune process to destroy the malignant cells, the remission of duration is usually short. Therefore, it seems that continuing treatment after SR of AML by a consolidation regimen or bone marrow transplantation, based on a risk-adapted treatment approach, may reduce the recurrence risk.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.